A Study of SGN-CD228A in Advanced Solid Tumors
Public ClinicalTrials.gov record NCT04042480. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Study of SGN-CD228A in Select Advanced Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This trial will study SGN-CD228A to find out whether it is an effective treatment for different kinds of cancer. It will also look at what side effects (unwanted effects) may occur. The study will have two parts. Part 1 of the study will find out how much SGN-CD228A should be given for treatment and how often. Part 2 of the study will use the dose found in Part 1 and look at how safe and effective the treatment is.
Study identification
- NCT ID
- NCT04042480
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 88 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 3, 2019 (Actual)
- Primary completion
- Mar 9, 2023 (Actual)
- Completion
- Mar 9, 2023 (Actual)
- Last update posted
- Mar 23, 2023
2019 – 2023
United States locations
- U.S. sites
- 10
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35249 | — |
| The Angeles Clinic and Research Institute | Los Angeles | California | 90025 | — |
| University of Chicago Medical Center | Chicago | Illinois | 60637 | — |
| Wake Forest Baptist Medical Center / Wake Forest University | Winston-Salem | North Carolina | 27157 | — |
| Case Western Reserve University / University Hospitals Cleveland Medical Center | Cleveland | Ohio | 44106 | — |
| Oregon Health and Science University | Portland | Oregon | 97239 | — |
| University of Pittsburgh Medical Center (UPMC)/Hillman Cancer Center | Pittsburgh | Pennsylvania | 15232 | — |
| Sanford Cancer Center | Sioux Falls | South Dakota | 57104 | — |
| MD Anderson Cancer Center / University of Texas | Houston | Texas | 77030 | — |
| South Texas Accelerated Research Therapeutics | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04042480, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 23, 2023 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04042480 live on ClinicalTrials.gov.